All public logs
Jump to navigation
Jump to search
Combined display of all available logs of wikidoc. You can narrow down the view by selecting a log type, the username (case-sensitive), or the affected page (also case-sensitive).
- 22:57, 3 May 2024 Kosar Doraghi talk contribs created page Xacduro- sulbactam and durlobactam (Created page with "{{DrugProjectFormSinglePage |authorTag=Kosar Doraghi, M.D. [mailto:k.doraghi@yahoo.com] |genericName=sulbactam and durlobactam |aOrAn=a |drugClass=co-packaged product containing sulbactam, a beta-lactam antibacterial and beta lactamase inhibitor, and durlobactam, a beta lactamase inhibitor, |indicationType=treatment |indication=hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP), caused by susceptible isolates of Acin...")
- 18:20, 3 May 2024 Alen Antony talk contribs created page Perfluorhexyloctane (Created page with "{{DrugProjectFormSinglePage |authorTag={{AAP}} |OTC=Yes |genericName=perfluorhexyloctane |aOrAn=a |drugClass=semifluorinated alkane |indicationType=treatment |indication=signs and symptoms of dry eye disease (DED). |adverseReactions=blurred vision. }}")
- 15:29, 2 May 2024 Alen Antony talk contribs created page Trofinetide (Created page with "{{DrugProjectFormSinglePage |authorTag={{AAP}} |genericName=trofinetide }}")
- 03:29, 2 May 2024 Alen Antony talk contribs created page Zavegepant (Created page with "{{DrugProjectFormSinglePage |authorTag={{AAP}} |genericName=zavegepant |aOrAn=a |drugClass=calcitonin gene-related peptide (CGRP) receptor antagonist. |indicationType=treatment |indication=acute migraine with or without aura in adults. |adverseReactions=taste disorders, nausea, nasal discomfort, and vomiting |fdaLIADAdult=The recommended dose is 10 mg given intranasally as a single spray in one nostril, as needed, with the maximum dosage at 10mg in 24 hours. |contraindic...")
- 21:51, 1 May 2024 Alen Antony talk contribs created page Omaveloxolone (Created page with "{{DrugProjectFormSinglePage |authorTag={{AAP}} |genericName=omaveloxolone }}")
- 15:46, 1 May 2024 Kosar Doraghi talk contribs created page Nirsevimab (Created page with "{{DrugProjectFormSinglePage |authorTag=Kosar Doraghi, M.D. [mailto:k.doraghi@yahoo.com] |genericName=Nirsevimab |aOrAn=a |drugClass=respiratory syncytial virus (RSV) F protein‑directed fusion inhibitor |indicationType=prevention |indication=RSV lower respiratory tract disease in: Neonates and infants born during or entering their first RSV season, and children up to 24 months of age who remain vulnerable to severe RSV disease through their second RSV season |hasBlackBo...")
- 15:31, 1 May 2024 Kosar Doraghi talk contribs created page File:IMG 1185.jpeg
- 15:31, 1 May 2024 Kosar Doraghi talk contribs uploaded File:IMG 1185.jpeg
- 15:29, 1 May 2024 Kosar Doraghi talk contribs created page File:IMG 1187.jpeg
- 15:29, 1 May 2024 Kosar Doraghi talk contribs uploaded File:IMG 1187.jpeg
- 14:19, 1 May 2024 User account Rithish Nimmagadda talk contribs was created by Alberto Castro Molina talk contribs
- 18:57, 30 April 2024 Alara E. Dagsali talk contribs created page Isosulfan Blue (Created page with "{{DrugProjectFormSinglePage |authorTag=Alara E.Dagsali |genericName=Lymphazurin |aOrAn=a |indicationType=treatment |indication=Isosulfan blue injection 1% upon subcutaneous administration, delineates lymphatic vessels draining the region of injection. It is an adjunct to lymphography in: primary and secondary lymphedema of the extremities; chyluria, chylous ascites or chylothorax; lymph node involvement by primary or secondary neoplasm; and lymph node response to therape...")
- 18:46, 30 April 2024 Alara E. Dagsali talk contribs created page Ibuprofen Lysine (Created page with "{{DrugProjectFormSinglePage |authorTag=Alara E.Dagsali |OTC=Yes |genericName=Ibuprofen lysine |aOrAn=a |indicationType=treatment |indication=Ibuprofen Lysine is indicated to close a clinically significant patent ductus arteriosus (PDA) in premature infants weighing between 500 and 1500 g, who are no more than 32 weeks gestational age when usual medical management (e.g., fluid restriction, diuretics, respiratory support, etc.) is ineffective. The clinical trial was conduc...")
- 18:27, 30 April 2024 Alara E. Dagsali talk contribs created page Prussian blue (Created page with "{{DrugProjectFormSinglePage |authorTag=Alara E.Dagsali |drugClass=RADIOGARDASE |indicationType=treatment |indication=Radiogardase is indicated for treatment of patients with known or suspected internal contamination with radioactive cesium and/or radioactive or non-radioactive thallium to increase their rates of elimination |adverseReactions=Most common adverse reaction (incidence >24%) was constipation Constipation was reported in 10 (24%) of 42 patients treated with R...")
- 18:14, 30 April 2024 Alara E. Dagsali talk contribs created page Botulism Antitoxin (Created page with "{{DrugProjectFormSinglePage |authorTag=Alara E.Dagsali |genericName=BAT |aOrAn=a |indicationType=treatment |indication=BAT [Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) – (Equine)] is a mixture of immune globulin fragments indicated for the treatment of symptomatic botulism following documented or suspected exposure to botulinum neurotoxin serotypes A, B, C, D, E, F, or G in adults and pediatric patients. |adverseReactions=The most common adverse reactions obse...")
- 15:23, 29 April 2024 Alara E. Dagsali talk contribs created page Trastuzumab emtansine (Created page with "{{DrugProjectFormSinglePage |authorTag=AlaraE.Dagsali |genericName=ado-trastuzumab emtansine |indicationType=treatment |indication=the treatment of patients with HER2-positive, metastatic breast cancer who previously received trastuzumab and a taxane, separately or in combination. Patients should have either: received prior therapy for metastatic disease, or developed disease recurrence during or within six months of completing adjuvant therapy. the adjuvant treatment...")
- 17:32, 26 April 2024 User account Jonathan Reyes talk contribs was created by Alberto Castro Molina talk contribs
- 22:39, 25 April 2024 Alara E. Dagsali talk contribs created page User:AED (Created page with "==Alara Ece Dagsali== '''Alara Ece Dagsali''' <br>'''Contact:''' email: alaraecedagsai99@gmail.com; +905313614710 ==Medical Education== *School of Medicine (M.D.): Istanbul Medipol University 2021- 2024 Demiroglu Bilim University 2018-2021 ==Pages authored/Co-authored/Collaborated== ===2023=== ====Authored:==== *Reni Syndrome ==Work Experience== *Wikidoc - Associate Editor-In-Chief, 2023 - Current *Yeditepe University Hospitals Cardiac Electrophysiology Lab, Ista...")
- 15:23, 25 April 2024 Alen Antony talk contribs created page Daprodustat (Created page with "{{DrugProjectFormSinglePage |authorTag={{AAP}} |genericName=daprodustat |aOrAn=a |drugClass=reversible inhibitor of HIF-PH1, PH2 and PH3. |indicationType=treatment |indication=anemia due to chronic kidney disease (CKD) in adults who have been receiving dialysis for at least four months. |hasBlackBoxWarning=Yes |adverseReactions=Hypertension, Abdominal pain, Dizzines, Hypersensitivity, and thrombotic vascular events like Myocardial infarction, stroke, pulmonary embolism,...")
- 23:04, 24 April 2024 Kosar Doraghi talk contribs created page File:IMG 1177.jpeg
- 23:04, 24 April 2024 Kosar Doraghi talk contribs uploaded File:IMG 1177.jpeg
- 22:59, 24 April 2024 Kosar Doraghi talk contribs created page File:IMG 1176.jpeg
- 22:59, 24 April 2024 Kosar Doraghi talk contribs uploaded File:IMG 1176.jpeg
- 21:21, 24 April 2024 Alara E. Dagsali talk contribs created page Template:AlaraE.Dagsali (Created page with " Alara Ece Dagsali, M.D.[mailto:alaraecedagsali99@gmail.com]")
- 21:14, 24 April 2024 Alara E. Dagsali talk contribs created page Tranexamic (Created page with "{{DrugProjectFormSinglePage |authorTag=Alara E.Dagsali |genericName=Tranexamic |aOrAn=a |drugClass=hemophilia drug |indicationType=prevention |indication=Tranexamic acid injection is indicated in patients with hemophilia for short-term use (2 to 8 days) to reduce or prevent hemorrhage and reduce the need for replacement therapy during and following tooth extraction. |adverseReactions=Thromboembolic Risk Seizures Hypersensitivity Reactions Visual Disturbances Dizzines...")
- 21:06, 24 April 2024 Alen Antony talk contribs created page Bexagliflozin (Created page with "{{DrugProjectFormSinglePage |authorTag={{AAP}} |genericName=bexagliflozin }}")
- 15:32, 23 April 2024 User account Malaika Hassan talk contribs was created by Alberto Castro Molina talk contribs
- 18:44, 22 April 2024 Alara E. Dagsali talk contribs created page File:D2f97c72-bbfb-426e-b742-6e25234ba1ff 2.jpg
- 18:44, 22 April 2024 Alara E. Dagsali talk contribs uploaded File:D2f97c72-bbfb-426e-b742-6e25234ba1ff 2.jpg
- 18:43, 22 April 2024 Alara E. Dagsali talk contribs created page File:Ae8d4ea7-c895-403b-a435-56dc4996a3b0.JPG
- 18:43, 22 April 2024 Alara E. Dagsali talk contribs uploaded File:Ae8d4ea7-c895-403b-a435-56dc4996a3b0.JPG
- 03:48, 21 April 2024 Kosar Doraghi talk contribs created page File:IMG 1052.jpeg
- 03:48, 21 April 2024 Kosar Doraghi talk contribs uploaded File:IMG 1052.jpeg
- 03:47, 21 April 2024 Kosar Doraghi talk contribs created page BRENZAVVY- bexagliflozin (Created page with "{{DrugProjectFormSinglePage |authorTag=Kosar Doraghi, M.D. [mailto:k.doraghi@yahoo.com] |genericName=BRENZAVVY- bexagliflozin |aOrAn=a |drugClass=sodium-glucose co-transporter 2 (SGLT2) inhibitor |indicationType=treatment |indication=glycemic control in adults with type 2 diabetes mellitus |hasBlackBoxWarning=Yes |adverseReactions=female genital mycotic infections, urinary tract infection and increased urination |blackBoxWarningTitle=Warnings |blackBoxWarningBody=*Not re...")
- 03:43, 21 April 2024 Kosar Doraghi talk contribs created page File:IMG 1050.jpeg
- 03:43, 21 April 2024 Kosar Doraghi talk contribs uploaded File:IMG 1050.jpeg
- 03:40, 21 April 2024 Kosar Doraghi talk contribs created page File:IMG 1051.jpeg
- 03:40, 21 April 2024 Kosar Doraghi talk contribs uploaded File:IMG 1051.jpeg
- 03:34, 21 April 2024 Kosar Doraghi talk contribs created page File:IMG 1049.jpeg
- 03:34, 21 April 2024 Kosar Doraghi talk contribs uploaded File:IMG 1049.jpeg
- 16:05, 20 April 2024 Imam Ali Shah talk contribs created page Template:IAS (Created page with "Associate Editor-In-Chief: Imam Ali Shah, MBBS; Chandka Medical College, Larkana Pakistan")
- 16:30, 19 April 2024 Kosar Doraghi talk contribs created page Sparsentan (Created page with "{{DrugProjectFormSinglePage |authorTag=Kosar Doraghi[mailto:k.doraghi@yahoo.com] |genericName=sparsentan |aOrAn=an |drugClass=endothelin and angiotensin II receptor antagonist |indicationType=treatment |indication=proteinuria(reduce) in adults with primary immunoglobulin A nephropathy (IgAN) at risk of rapid disease progression, generally a urine protein-to-creatinine ratio (UPCR) ≥1.5 g/g |hasBlackBoxWarning=Yes |adverseReactions=Hepatotoxicity, Embryo-Fetal Tox...")
- 16:24, 19 April 2024 Kosar Doraghi talk contribs created page File:IMG 1046.jpeg
- 16:24, 19 April 2024 Kosar Doraghi talk contribs uploaded File:IMG 1046.jpeg
- 16:14, 19 April 2024 Kosar Doraghi talk contribs created page File:IMG 1045.jpeg
- 16:14, 19 April 2024 Kosar Doraghi talk contribs uploaded File:IMG 1045.jpeg
- 16:11, 19 April 2024 Kosar Doraghi talk contribs created page File:IMG 1047.jpeg
- 16:11, 19 April 2024 Kosar Doraghi talk contribs uploaded File:IMG 1047.jpeg
- 16:05, 19 April 2024 Kosar Doraghi talk contribs created page File:IMG 1044.jpeg
- 16:05, 19 April 2024 Kosar Doraghi talk contribs uploaded File:IMG 1044.jpeg
- 19:33, 17 April 2024 Hafiza Amna Qadeer talk contribs created page SCAPULOPERONEAL SPINAL MUSCULAR ATROPHY (Created blank page)
- 08:08, 17 April 2024 Edzelco talk contribs created page Elranatamab-bcmm (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} }}")
- 08:08, 17 April 2024 Edzelco talk contribs created page Palovarotene (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} }}")
- 08:08, 17 April 2024 Edzelco talk contribs created page Pozelimab-bbfg (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} }}")
- 08:07, 17 April 2024 Edzelco talk contribs created page Motixafortide (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} }}")
- 08:07, 17 April 2024 Edzelco talk contribs created page Momelotinib (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} }}")
- 08:06, 17 April 2024 Edzelco talk contribs created page Cipaglucosidase alfa-atga (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} }}")
- 08:05, 17 April 2024 Edzelco talk contribs created page Etrasimod (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} }}")
- 08:05, 17 April 2024 Edzelco talk contribs created page Zilucoplan (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} }}")
- 08:04, 17 April 2024 Edzelco talk contribs created page Bimekizumab (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} }}")
- 08:04, 17 April 2024 Edzelco talk contribs created page Vamorolone (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} }}")
- 08:04, 17 April 2024 Edzelco talk contribs created page Mirikizumab-mrkz (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} }}")
- 08:03, 17 April 2024 Edzelco talk contribs created page Toripalimab-tpzi (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} }}")
- 08:02, 17 April 2024 Edzelco talk contribs created page Fruquintinib (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} |genericName=fruquintinib |aOrAn=a |drugClass=kinase inhibitor |indicationType=treatment |indication=adult patients with metastatic colorectal cancer (mCRC) who have been previously treated with fluoropyrimidine‑, oxaliplatin‑, and irinotecan‑based chemotherapy, an anti‑VEGF therapy, and, if RAS wild‑type and medically appropriate, an anti-EGFR therapy |fdaLIADAdult=Recommended Dosage The recommended dose of F...")
- 07:52, 17 April 2024 Edzelco talk contribs created page Taurolidine, heparin (Created page with "{{DrugProjectFormSinglePage |authorTag={{Edzelco}} |genericName=taurolidine, heparin |aOrAn=a |drugClass=combination of taurolidine, a thiadiazinane antimicrobial, and heparin, an anti-coagulant |indicationType=prevention |indication=atheter-related bloodstream infections (CRBSI) in adult patients with kidney failure receiving chronic hemodialysis (HD) through a central venous catheter (CVC). This drug is indicated for use in a limited and specific population of patients...")
- 07:43, 17 April 2024 Edzelco talk contribs created page Repotrectinib (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} |genericName=repotrectinib |aOrAn=a |drugClass=kinase inhibitor |indicationType=treatment |indication=adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) |contraindications=None |warnings=5.1 Central Nervous System Adverse Reactions AUGTYRO can cause central nervous system adverse reactions. Among the 351 patients who received AUGTYRO in Study TRIDENT-1, a broad spectru...")
- 07:32, 17 April 2024 Edzelco talk contribs created page Efbemalenograstim alfa-vuxw (Created page with "{{DrugProjectFormSinglePage |genericName=efbemalenograstim alfa-vuxw |aOrAn=a |drugClass=leukocyte growth factor |indicationType=prevention |indication=incidence of infection, as manifested by febrile neutropenia, in adult patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia |fdaLIADAdult=Recommended Dose: 20 mg administered subcutaneously once per chemotherapy cycle....")
- 05:50, 16 April 2024 Edzelco talk contribs created page Capivasertib (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} |genericName=Capivasertib |aOrAn=a |drugClass=kinase inhibitor in combination with fulvestrant |indicationType=treatment |indication=adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations as detected by an FDA-approved test following progression on at least one endocrine-based...")
- 05:27, 16 April 2024 Edzelco talk contribs created page Iptacopan (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} |genericName=iptacopan |aOrAn=a |drugClass=complement factor B inhibitor |indicationType=treatment |indication=paroxysmal nocturnal hemoglobinuria |blackBoxWarningTitle=WARNING: SERIOUS INFECTIONS CAUSED BY ENCAPSULATED BACTERIA |blackBoxWarningBody=<span style="clear;"> FABHALTA increases the risk of serious and life-threatening infections caused by encapsulated bacteria, including Streptococcus pneumoniae, Neisseria me...")
- 07:24, 15 April 2024 Edzelco talk contribs created page Vutrisiran (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} |genericName=vutrisiran |aOrAn=a |drugClass=transthyretin-directed small interfering RNA |indicationType=treatment |indication=polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults. |adverseReactions=pain in extremity, arthralgia, dyspnea, and decreased vitamin A levels. |fdaLIADAdult=Recommended Dosage The recommended dosage of AMVUTTRA is 25 mg administered by subcutaneous inj...")
- 20:06, 11 April 2024 User account Bilal Farhat Ali talk contribs was created by Alberto Castro Molina talk contribs
- 19:20, 10 April 2024 Kosar Doraghi talk contribs created page File:IMG 1037.jpeg
- 19:20, 10 April 2024 Kosar Doraghi talk contribs uploaded File:IMG 1037.jpeg
- 23:28, 3 April 2024 Kosar Doraghi talk contribs created page File:IMG 0918.jpeg
- 23:28, 3 April 2024 Kosar Doraghi talk contribs uploaded File:IMG 0918.jpeg
- 20:13, 27 March 2024 M. Arsalan Bashir talk contribs created page User:M. Arsalan Bashir (Created page with "I’m an aspiring Neuroscientist and Neurology MD candidate, having earned my MBBS degree from Ziauddin University. My journey has led me to research, where I am wholeheartedly committed to enhancing treatment methods and increasing knowledge to challenge the stigma often linked with neurological conditions.") Tag: Visual edit
- 11:08, 27 March 2024 Imam Ali Shah talk contribs created page File:Bismuth Subnitrate Package and Label Display Panel.jpg
- 11:08, 27 March 2024 Imam Ali Shah talk contribs uploaded File:Bismuth Subnitrate Package and Label Display Panel.jpg
- 09:51, 27 March 2024 Imam Ali Shah talk contribs created page Bismuth subnitrate (Created page with "dasda") Tag: Visual edit
- 09:13, 26 March 2024 Imam Ali Shah talk contribs created page User:Imam Ali Shah (Created page with "=='''Imam Ali Shah, MBBS'''== Contact:Email: imamshah.med@gmail.com ==Medical Education== *'''2017-2022''' **MBBS Chandka Medical College, Pakistan ==Professional Affiliations== *Profesional Aff...")
- 08:33, 21 March 2024 Alara E. Dagsali talk contribs created page Norelgestromin (Created page with "{{DrugProjectFormSinglePage |authorTag=Alara E.Dagsali |OTC=Yes |genericName=NORELGESTROMIN AND ETHINLY ESTRADIOL patch |indicationType=prevention |indication=Norelgestromin and ethinyl estradiol transdermal system is indicated for the prevention of pregnancy in women with a body mass index (BMI) < 30 kg/m for whom a combined hormonal contraceptive is appropriate. |hasBlackBoxWarning=Yes |adverseReactions=The following serious adverse reactions with the use of co...")
- 05:58, 21 March 2024 Kosar Doraghi talk contribs created page File:IMG 0885.jpeg
- 05:58, 21 March 2024 Kosar Doraghi talk contribs uploaded File:IMG 0885.jpeg
- 23:07, 19 March 2024 Kosar Doraghi talk contribs created page Ryzneuta (Created page with "{{DrugProjectFormSinglePage |authorTag=Kosar Doraghi, M.D.[mailto:k.doraghi@yahoo.com]] |genericName=RYZNEUTA -Efbemalenograstim alfa-vuxw |aOrAn=a |drugClass=leukocyte growth factor |indicationType=treatment |indication=and decrease the incidence of infection, as manifested by [febrile neutropenia], in adult patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia |h...")
- 10:01, 12 March 2024 Hafiza Amna Qadeer talk contribs created page Rezafungin (Created page with "{{DrugProjectFormSinglePage |authorTag=HAFIZA AMNA QADEER |OTC=Yes |genericName=REZAFUNGIN |aOrAn=an |drugClass=echinocandin antifungal |indicationType=treatment }}")
- 17:24, 5 March 2024 User account Imam Ali Shah talk contribs was created by Alberto Castro Molina talk contribs
- 17:17, 5 March 2024 User account M. Arsalan Bashir talk contribs was created by Alberto Castro Molina talk contribs
- 18:02, 3 March 2024 Marshallsumter talk contribs created page Non-degenerate nucleotides per response element (Created page with " {| class="wikitable sortable" |+ Number of non-degenerate nucleotides versus number of response elements |- ! Number of nucleotides !! Letters of nucleotides !! Number of response elements !! Average ± deviation !! Order of list |- | 1 || A || 295 || 295.0 ± 0.0 || 1 |- | 1 || T || 285 || - || 1 |- | 1 || G || 286 || - || 3 |- | 1(4) || C || 300 || 291.5 ± 6 || 5 |- | 2 || AA || 105 || 105 ± 0.0 || 1 |- | 2 || AT || 105 || 105 ± 0.0 || 1 |- | 2 || TA || 74 |...")
- 02:16, 29 February 2024 Alen Antony talk contribs created page Lecanemab-irmb (Created page with "{{DrugProjectFormSinglePage |authorTag={{AAP}} |genericName=lecanemab-irmb |aOrAn=a |drugClass=recombinant humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody |indicationType=treatment |indication=Alzheimer’s disease. This drug is ideally initiated during the early phase of dementia or mild cognitive impairment (which was the population tested in the clinical trials of this drug). |hasBlackBoxWarning=Yes |adverseReactions=Amyloid Related Imaging Abnorma...")
- 02:40, 28 February 2024 Kosar Doraghi talk contribs created page Vonoprazan fumarate (Created page with "{{DrugProjectFormSinglePage |authorTag=Kosar Doraghi, M.D.[mailto:k.doraghi@yahoo.com] |genericName=vonoprazan fumarate |aOrAn=a |drugClass=potassium-competitive acid blocker |indicationType=treatment |indication=all grades of erosive esophagitis and relief of heartburn associated with erosive esophagitis in adults. *to maintain healing of all grades of erosive esophagitis and relief of heartburn associated with erosive esophagitis in adults. *in combinatio...")
- 21:36, 23 February 2024 Kosar Doraghi talk contribs created page Nedosiran (Created page with "{{DrugProjectFormSinglePage |authorTag={{KDRG}} |genericName=nedosiran |aOrAn=an |drugClass=LDHA-directed small interfering RNA |indicationType=treatment |indication=lower urinary oxalate levels in children 9 years of age and older and adults with primary hyperoxaluria type 1 (PH1) and relatively preserved kidney function, e.g., eGFR ≥ 30 mL/min/1.73 m2 |adverseReactions=injection site reactions |fdaLIADAdult=RIVFLOZA Injection 160 mg/mL is a clear, colorless-t...")
- 21:25, 23 February 2024 Kosar Doraghi talk contribs created page File:IMG 0866.jpeg
- 21:25, 23 February 2024 Kosar Doraghi talk contribs uploaded File:IMG 0866.jpeg
- 21:24, 23 February 2024 Kosar Doraghi talk contribs created page File:IMG 0864.jpeg
- 21:24, 23 February 2024 Kosar Doraghi talk contribs uploaded File:IMG 0864.jpeg
- 21:21, 23 February 2024 Kosar Doraghi talk contribs created page File:IMG 0858.jpeg
- 21:21, 23 February 2024 Kosar Doraghi talk contribs uploaded File:IMG 0858.jpeg
- 21:20, 23 February 2024 Kosar Doraghi talk contribs created page File:IMG 0861.jpeg
- 21:20, 23 February 2024 Kosar Doraghi talk contribs uploaded File:IMG 0861.jpeg
- 21:20, 23 February 2024 Kosar Doraghi talk contribs created page File:IMG 0860.jpeg
- 21:20, 23 February 2024 Kosar Doraghi talk contribs uploaded File:IMG 0860.jpeg
- 21:19, 23 February 2024 Kosar Doraghi talk contribs created page File:IMG 0859.jpeg
- 21:19, 23 February 2024 Kosar Doraghi talk contribs uploaded File:IMG 0859.jpeg
- 21:17, 23 February 2024 Kosar Doraghi talk contribs created page File:IMG 0867.jpeg
- 21:17, 23 February 2024 Kosar Doraghi talk contribs uploaded File:IMG 0867.jpeg
- 21:11, 23 February 2024 Kosar Doraghi talk contribs created page File:IMG 0857.jpeg
- 21:11, 23 February 2024 Kosar Doraghi talk contribs uploaded File:IMG 0857.jpeg
- 21:09, 23 February 2024 Kosar Doraghi talk contribs created page File:IMG 0856.jpeg
- 21:09, 23 February 2024 Kosar Doraghi talk contribs uploaded File:IMG 0856.jpeg
- 21:06, 23 February 2024 Kosar Doraghi talk contribs created page File:IMG 0855.jpeg
- 21:06, 23 February 2024 Kosar Doraghi talk contribs uploaded File:IMG 0855.jpeg
- 21:05, 23 February 2024 Kosar Doraghi talk contribs created page File:IMG 0853.jpeg
- 21:05, 23 February 2024 Kosar Doraghi talk contribs uploaded File:IMG 0853.jpeg
- 20:53, 23 February 2024 Kosar Doraghi talk contribs created page File:IMG 0852.jpeg
- 20:53, 23 February 2024 Kosar Doraghi talk contribs uploaded File:IMG 0852.jpeg
- 04:16, 23 February 2024 Kosar Doraghi talk contribs created page Nirogacestat (Created page with "{{DrugProjectFormSinglePage |authorTag={{KDRG}} |genericName=nirogacestat |aOrAn=a |drugClass=gamma secretase inhibitor |indicationType=treatment |indication=adult patients with progressing desmoid tumors who require systemic treatment |hasBlackBoxWarning=Yes |adverseReactions=diarrhea, ovarian toxicity, rash, nausea, fatigue, stomatitis, headache, abdominal pain, cough, alopecia, upper respiratory tract infection and [...")
- 04:05, 23 February 2024 Kosar Doraghi talk contribs created page File:IMG 0851.jpeg
- 04:05, 23 February 2024 Kosar Doraghi talk contribs uploaded File:IMG 0851.jpeg
- 04:00, 23 February 2024 Kosar Doraghi talk contribs created page File:IMG 0848.jpeg
- 04:00, 23 February 2024 Kosar Doraghi talk contribs uploaded File:IMG 0848.jpeg
- 03:59, 23 February 2024 Kosar Doraghi talk contribs created page File:IMG 0850.jpeg
- 03:59, 23 February 2024 Kosar Doraghi talk contribs uploaded File:IMG 0850.jpeg
- 03:57, 23 February 2024 Kosar Doraghi talk contribs created page File:IMG 0847.jpeg
- 03:57, 23 February 2024 Kosar Doraghi talk contribs uploaded File:IMG 0847.jpeg
- 16:45, 22 February 2024 Mohammad Nikoohemmat talk contribs created page Sandbox:MNH (Created page with "=====bold kardan subtitle=====")
- 13:31, 22 February 2024 Mohammad Nikoohemmat talk contribs created page Birch triterpenes (Created page with "{{DrugProjectFormSinglePage |authorTag=Mohammad Nikoohemmat |genericName=birch triterpenes }}")
- 13:24, 22 February 2024 Mohammad Nikoohemmat talk contribs created page Eplontersen (Created page with "{{DrugProjectFormSinglePage |authorTag=Mohammad Nikoohemmat |genericName=Eplontersen |aOrAn=a |drugClass=transthyretin-directed antisense oligonucleotide |indicationType=treatment |indication=WAINUA is indicated for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults. |adverseReactions=Most common adverse reactions (that occurred in at least 9% of patients treated with WAINUA) were vitamin A decreased and vomiting. |fdaLIADAdult...")
- 12:33, 22 February 2024 Mohammad Nikoohemmat talk contribs created page Template:MNH (Created page with "Mohammad Nikoohemmat, M.D.[mailto:mohammadnikoo1375@gmail.com]")
- 16:38, 21 February 2024 Badgettrg talk contribs created page Template:Math2 (Created page with "<span class="texhtml {{#if:{{{big|}}}{{{size|}}}|texhtml-big}}" {{#if:{{{big|}}}{{{size|}}}|style="font-size:{{{size|165%}}};"}}>{{{1}}}</span><!-- -->{{#invoke:Check for unknown parameters|check | unknown = {{main other|_VALUE_}} | showblankpositional=1 | preview = unknown parameter "_VALUE_" (consider using <code>{{!}}1=</code>, <code><nowiki>{{!}}</nowiki></code>, <code><nowiki>{{=}}</nowiki></code>) | 1 | big | si...")
- 06:21, 21 February 2024 Alen Antony talk contribs created page Olutasidenib (Created page with "{{DrugProjectFormSinglePage |authorTag={{AAP}} |genericName=Olutasidenib |aOrAn=a |drugClass=isocitrate dehydrogenase-1 (IDH1) inhibitor |indicationType=treatment |indication=relapsed or refractory acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation. |hasBlackBoxWarning=Yes |adverseReactions=nausea, vomiting, diarrhea, constipation, abdominal pain, decreased appetite, mucositis, arthralgia, fatigue, pyrexia...")
- 14:13, 20 February 2024 Badgettrg talk contribs created page Treatment outcome (Created page with "{{SI}} {{RGB}} In Quality of Health Care, '''{{PAGENAME}}''' is defined as "Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series."<ref>{{MeSH}}</ref> ==Statistical methods== * The minimal clinically important differences (MCID) has been proposed as >0.5 standard deviation imp...")
- 15:11, 19 February 2024 Matt Pijoan talk contribs created page Template:Image (Created page with "<templatestyles src="Image/styles.css"/><div class="t-image {{#ifeq:{{{padding|}}}|no||t-image-padding}}" {{#if:{{{width|}}}|style="max-width:{{{width}}}%"}}> [[File:{{{file|File:MattP(1).png}}}|{{{imagewidth|400}}}px|{{#ifeq:{{{border|}}}|yes|border{{!}}}}alt={{{caption|}}}|{{#if:{{{link|}}}|link={{{link|}}}}}]]{{#if: {{{caption|}}}| <p class="t-image-caption"> {{{caption}}} </p>}} </div><noinclude> {{documentation|content= {{Uses TemplateStyles|Template:Image/styles.cs...")
- 16:17, 18 February 2024 Badgettrg talk contribs created page Back pain monitoring response to therapy (Created page with "__NOTOC__ {{Back pain}} {{CMG}} {{AE}} {{ZMalik}} ==Overview== The Oswestry low back pain disability questionnaire (ODQ) can measure the response to therapy.<ref name="pmid6450426">{{cite journal| author=Fairbank JC, Couper J, Davies JB, O'Brien JP| title=The Oswestry low back pain disability questionnaire. | journal=Physiotherapy | year= 1980 | volume= 66 | issue= 8 | pages= 271-3 | pmid=6450426 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi...")
- 03:15, 16 February 2024 Kosar Doraghi talk contribs created page Lasmiditan (Created page with "{{DrugProjectFormSinglePage |authorTag={{KDRG}} |genericName=Lasmiditan (REYVOW) |aOrAn=a |drugClass=serotonin (5-HT) 1F receptor agonist |indicationType=treatment |indication=migraine with or without aura in adults |hasBlackBoxWarning=Yes |adverseReactions=dizziness, fatigue, paresthesia, and sedation |blackBoxWarningTitle=Warning |blackBoxWarningBody=Driving Impairment: *Central Nervous System (CNS) Depression: Do not use in combination...")
- 03:03, 16 February 2024 Kosar Doraghi talk contribs created page File:IMG 0837.jpeg
- 03:03, 16 February 2024 Kosar Doraghi talk contribs uploaded File:IMG 0837.jpeg
- 02:58, 16 February 2024 Kosar Doraghi talk contribs created page File:IMG 0839.jpeg
- 02:58, 16 February 2024 Kosar Doraghi talk contribs uploaded File:IMG 0839.jpeg
- 02:56, 16 February 2024 Kosar Doraghi talk contribs created page File:IMG 0838.jpeg
- 02:56, 16 February 2024 Kosar Doraghi talk contribs uploaded File:IMG 0838.jpeg
- 06:30, 15 February 2024 Alen Antony talk contribs created page Lenacapavir (Created page with "{{DrugProjectFormSinglePage |authorTag={{AAP}} |genericName=lenacapavir }}")
- 02:00, 15 February 2024 Alara E. Dagsali talk contribs created page 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes: Developed by the task force on the management of cardiovascular disease in patients with diabetes of the European Society of Cardiology (ESC) (Created page with "{{ADA guidelines}} {{CMG}} {{AE}} {{SCh}}; {{MehdiP}}; {{TarekNafee}} ==2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes: Developed by the task force on the management of cardiovascular disease in patients with diabetes of the European Society of Cardiology (ESC)<ref name="pmid37622663">{{cite journal| author=Marx N, Federici M, Schütt K, Müller-Wieland D, Ajjan RA, Antunes MJ | display-authors=etal| title=2023 ESC Guidelines f...")
- 01:01, 15 February 2024 Kosar Doraghi talk contribs created page Ponesimod (Created page with "{{DrugProjectFormSinglePage |authorTag={{KDRG}} |genericName=Ponesimod (PONVORY) |aOrAn=a |drugClass=sphingosine 1-phosphate receptor modulator |indicationType=treatment |indication=relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults |hasBlackBoxWarning=Yes |adverseReactions=upper respiratory tract infection, hepatic transaminase elevation, and ...")
- 00:56, 15 February 2024 Kosar Doraghi talk contribs created page File:IMG 0834.jpeg
- 00:56, 15 February 2024 Kosar Doraghi talk contribs uploaded File:IMG 0834.jpeg
- 00:55, 15 February 2024 Kosar Doraghi talk contribs created page File:IMG 0833.jpeg
- 00:55, 15 February 2024 Kosar Doraghi talk contribs uploaded File:IMG 0833.jpeg
- 00:49, 15 February 2024 Kosar Doraghi talk contribs created page File:IMG 0832.jpeg
- 00:49, 15 February 2024 Kosar Doraghi talk contribs uploaded File:IMG 0832.jpeg
- 00:48, 15 February 2024 Kosar Doraghi talk contribs created page File:IMG 0829.jpeg
- 00:48, 15 February 2024 Kosar Doraghi talk contribs uploaded File:IMG 0829.jpeg
- 00:46, 15 February 2024 Kosar Doraghi talk contribs created page File:IMG 0831.jpeg
- 00:46, 15 February 2024 Kosar Doraghi talk contribs uploaded File:IMG 0831.jpeg
- 21:25, 14 February 2024 Alen Antony talk contribs created page Tirzepatide (Created page with "{{DrugProjectFormSinglePage |authorTag={{AAP}} |genericName=tirzepatide |aOrAn=a |drugClass=glucagon-like peptide-1 (GLP-1) receptor agonist |indicationType=treatment |indication=type 2 diabetes mellitus in adults in adjunct to diet and exercise. |hasBlackBoxWarning=Yes |adverseReactions=pancreatitis,hypoglycemia with concomitant use of insulin or insulin secretagogues, acute kidney injury, severe gastrointestinal disease, acute gallbladder disease, dia...")
- 18:30, 14 February 2024 Kosar Doraghi talk contribs created page Dasiglucagon (Created page with "{{DrugProjectFormSinglePage |authorTag={{KDRG}} |genericName=Dasiglucagon (ZEGALOGUE) |aOrAn=an |drugClass=anti-hypoglycemic |indicationType=treatment |indication=severe hypoglycemia in pediatric and adult patients with diabetes aged 6 years and older |hasBlackBoxWarning=Yes |adverseReactions=nausea, vomiting, headache, diarrhea, and injection site pain |blackBoxWarningTitle=Allergic reactions |blackBoxWarningBody=increase in blood pressure in Patients wi...")
- 18:17, 14 February 2024 Kosar Doraghi talk contribs created page File:IMG 0828.jpeg
- 18:17, 14 February 2024 Kosar Doraghi talk contribs uploaded File:IMG 0828.jpeg
- 18:16, 14 February 2024 Kosar Doraghi talk contribs created page File:IMG 0827.jpeg
- 18:16, 14 February 2024 Kosar Doraghi talk contribs uploaded File:IMG 0827.jpeg
- 18:13, 14 February 2024 Kosar Doraghi talk contribs created page File:IMG 0822.jpeg
- 18:13, 14 February 2024 Kosar Doraghi talk contribs uploaded File:IMG 0822.jpeg
- 18:12, 14 February 2024 Kosar Doraghi talk contribs created page File:IMG 0826.jpeg
- 18:12, 14 February 2024 Kosar Doraghi talk contribs uploaded File:IMG 0826.jpeg
- 18:07, 14 February 2024 Kosar Doraghi talk contribs created page File:IMG 0824.jpeg
- 18:07, 14 February 2024 Kosar Doraghi talk contribs uploaded File:IMG 0824.jpeg
- 18:05, 14 February 2024 Kosar Doraghi talk contribs created page File:IMG 0823.jpeg
- 18:05, 14 February 2024 Kosar Doraghi talk contribs uploaded File:IMG 0823.jpeg
- 17:59, 14 February 2024 Kosar Doraghi talk contribs created page File:IMG 0820.jpeg
- 17:59, 14 February 2024 Kosar Doraghi talk contribs uploaded File:IMG 0820.jpeg
- 17:58, 14 February 2024 Kosar Doraghi talk contribs created page File:IMG 0819.jpeg
- 17:58, 14 February 2024 Kosar Doraghi talk contribs uploaded File:IMG 0819.jpeg
- 07:05, 14 February 2024 Alen Antony talk contribs created page Spesolimab-sbzo (Created page with "{{DrugProjectFormSinglePage |authorTag={{AAP}} |genericName=Spesolimab-sbzo |drugClass=humanized monoclonal Immunoglobulin G1 antibody |indicationType=treatment |indication=generalized pustular psoriasis (GPP) flares in adults. |adverseReactions=infections, nausea, vomiting, headache, fatigue, Infusion site hematoma and bruising. |fdaLIADAdult=SPEVIGO is indicated for the treatment of generalized pustular psoriasis (GPP) flares in adults. SPEVIGO is administer...")
- 21:57, 13 February 2024 Kosar Doraghi talk contribs created page File:IMG 0813.jpeg
- 21:57, 13 February 2024 Kosar Doraghi talk contribs uploaded File:IMG 0813.jpeg
- 21:56, 13 February 2024 Kosar Doraghi talk contribs created page File:IMG 0812.jpeg
- 21:56, 13 February 2024 Kosar Doraghi talk contribs uploaded File:IMG 0812.jpeg
- 21:54, 13 February 2024 Kosar Doraghi talk contribs created page File:IMG 0817.jpeg
- 21:54, 13 February 2024 Kosar Doraghi talk contribs uploaded File:IMG 0817.jpeg
- 21:51, 13 February 2024 Kosar Doraghi talk contribs created page File:IMG 0818.jpeg
- 21:51, 13 February 2024 Kosar Doraghi talk contribs uploaded File:IMG 0818.jpeg
- 21:50, 13 February 2024 Kosar Doraghi talk contribs created page File:IMG 0816.jpeg
- 21:50, 13 February 2024 Kosar Doraghi talk contribs uploaded File:IMG 0816.jpeg
- 21:47, 13 February 2024 Kosar Doraghi talk contribs created page Vericiguat (Created page with "{{DrugProjectFormSinglePage |authorTag={{KDRG}} |genericName=VERQUVO-vericiguat |aOrAn=a |drugClass=soluble guanylate cyclase (sGC) stimulator |indicationType=treatment |indication=heart failure with reduced ejection fraction (HFrEF), reduce the risk of cardiovascular death and heart failure (HF) hospitalization following a hospitalization for heart failure or need for outpatient IV diuretics, in adults with symptomatic chronic HF and ejection fraction less t...")
- 21:43, 13 February 2024 Kosar Doraghi talk contribs created page File:IMG 0815.jpeg
- 21:43, 13 February 2024 Kosar Doraghi talk contribs uploaded File:IMG 0815.jpeg
- 03:20, 13 February 2024 Kosar Doraghi talk contribs created page File:IMG 0810.jpeg
- 03:20, 13 February 2024 Kosar Doraghi talk contribs uploaded File:IMG 0810.jpeg
- 03:18, 13 February 2024 Kosar Doraghi talk contribs created page Tapinarof (Created page with "{{DrugProjectFormSinglePage |authorTag={{KDRG}} |genericName=VTAMA- tapinarof cream |aOrAn=an |drugClass=aryl hydrocarbon receptor agonist |indicationType=treatment |indication=plaque psoriasis in adults |adverseReactions=folliculitis, nasopharyngitis, contact dermatitis, headache, and pruritus |fdaLIADAdult=Cream, 1% Each gram of VTAMA cream contains 10 mg of tapinarof in a white to off-white cream. *Apply a thin layer of VTAMA cream to affected ar...")
- 03:14, 13 February 2024 Kosar Doraghi talk contribs created page File:IMG 0809.jpeg
- 03:14, 13 February 2024 Kosar Doraghi talk contribs uploaded File:IMG 0809.jpeg
- 03:12, 13 February 2024 Kosar Doraghi talk contribs created page File:IMG 0808.jpeg
- 03:12, 13 February 2024 Kosar Doraghi talk contribs uploaded File:IMG 0808.jpeg
- 03:10, 13 February 2024 Kosar Doraghi talk contribs created page File:IMG 0807.jpeg
- 03:10, 13 February 2024 Kosar Doraghi talk contribs uploaded File:IMG 0807.jpeg
- 22:30, 12 February 2024 Alen Antony talk contribs created page Mosunetuzumab-axgb (Created page with "{{DrugProjectFormSinglePage |authorTag={{AAP}} |genericName=mosunetuzumab-axgb |aOrAn=a |drugClass=humanized monoclonal antibody |indicationType=treatment |indication=relapsing or refractory follicular lymphoma in adults after 2 or more lines of systemic therapy. |hasBlackBoxWarning=Yes |adverseReactions=cytokine release syndrome, fatigue, rash, pyrexia, and headache. |blackBoxWarningTitle=Cytokine Release Syndrome (CRS) |blackBoxWarningBody=Cytok...")
- 17:40, 12 February 2024 Kosar Doraghi talk contribs created page Spevigo- spesolimab-sbz (Created page with "{{DrugProjectFormSinglePage |authorTag={{KDRG}} |genericName=spesolimab-sbzo |aOrAn=an |drugClass=interleukin-36 receptor antagonis |indicationType=treatment |indication=generalized pustular psoriasis flares in adults |hasBlackBoxWarning=Yes |adverseReactions=asthenia and fatigue, nausea and vomiting, headache, pruritus and prurigo, infusion site hematoma and bruising, and urinary tract infection. |blackBoxWarningTitle=Warning: Hyp...")
- 22:23, 11 February 2024 Edzelco talk contribs created page Mavacamten (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} |genericName=mavacamten |aOrAn=a |drugClass=cardiac myosin inhibitor |indicationType=treatment |indication=adults with symptomatic New York Heart Association (NYHA) class II-III obstructive hypertrophic cardiomyopathy (HCM) to improve functional capacity and symptoms |hasBlackBoxWarning=Yes |adverseReactions=dizziness (27%) and syncope (6%) |blackBoxWarningTitle=WARNING: RISK OF HEART...")
- 06:13, 11 February 2024 Alen Antony talk contribs created page Template:AAP (Created page with "Alen Antony Pathil, M.D.[mailto:alenantony657@gmail.com]")
- 19:04, 10 February 2024 Edzelco talk contribs created page Oteseconazole (Created page with "{{DrugProjectFormSinglePage |genericName=oteseconazole |aOrAn=an |drugClass=azole antifungal |indicationType=prevention |indication=recurrent vulvovaginal candidiasis (RVVC) in females with a history of RVVC who are NOT of reproductive potential |adverseReactions=headache and nausea |fdaLIADAdult=VIVJOA Capsules: 150 mg of oteseconazole in lavender hard gelatin capsules imprinted with OTE 150 in black ink. Fluconazole is not supplied in the carton. |co...")
- 19:02, 10 February 2024 Edzelco talk contribs created page File:VIVJOA label3.png
- 19:02, 10 February 2024 Edzelco talk contribs uploaded File:VIVJOA label3.png
- 19:02, 10 February 2024 Edzelco talk contribs created page File:VIVJOA label2.png
- 19:02, 10 February 2024 Edzelco talk contribs uploaded File:VIVJOA label2.png
- 19:02, 10 February 2024 Edzelco talk contribs created page File:VIVJOA label.png
- 19:02, 10 February 2024 Edzelco talk contribs uploaded File:VIVJOA label.png
- 19:02, 10 February 2024 Edzelco talk contribs created page File:VIVJOA structure.png
- 19:02, 10 February 2024 Edzelco talk contribs uploaded File:VIVJOA structure.png
- 06:17, 10 February 2024 Kosar Doraghi talk contribs created page Ublituximab-xiiy (Created page with "{{DrugProjectFormSinglePage |authorTag=Kosar Doraghi, M.D.[mailto:k.doraghi@yahoo.com] |genericName=BRIUMVI™ (ublituximab-xiiy |aOrAn=a |drugClass=CD20-directed cytolytic antibody |indicationType=treatment |indication=relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults |hasBlackBoxWarning=Yes |adverseReactions=infusion reactions and upper respiratory...")
- 06:14, 10 February 2024 Kosar Doraghi talk contribs created page File:IMG 0806.jpeg
- 06:14, 10 February 2024 Kosar Doraghi talk contribs uploaded File:IMG 0806.jpeg
- 06:13, 10 February 2024 Kosar Doraghi talk contribs created page File:IMG 0805.jpeg
- 06:13, 10 February 2024 Kosar Doraghi talk contribs uploaded File:IMG 0805.jpeg
- 06:09, 10 February 2024 Kosar Doraghi talk contribs created page File:IMG 0799.jpeg
- 06:09, 10 February 2024 Kosar Doraghi talk contribs uploaded File:IMG 0799.jpeg
- 22:35, 7 February 2024 User account Alen Antony talk contribs was created by Alberto Castro Molina talk contribs
- 17:15, 7 February 2024 Kosar Doraghi talk contribs created page LYTGOBI- futibatinib (Created page with "{{DrugProjectFormSinglePage |authorTag=Kosar Doraghi, M.D.[mailto:k.doraghi@yahoo.com] |genericName=Futibatinib |aOrAn=a |drugClass=kinase inhibitor |indicationType=treatment |indication=adult patients with previously treated, unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma harboring fibroblast growth factor receptor 2 (FGFR2) gene fusions or other rearrangements. This indication is approved under accelerated approval based on overall respons...")
- 05:03, 7 February 2024 Kosar Doraghi talk contribs created page File:IMG 0790.jpeg
- 05:03, 7 February 2024 Kosar Doraghi talk contribs uploaded File:IMG 0790.jpeg
- 05:01, 7 February 2024 Kosar Doraghi talk contribs created page File:IMG 0787.jpeg
- 05:01, 7 February 2024 Kosar Doraghi talk contribs uploaded File:IMG 0787.jpeg
- 04:56, 7 February 2024 Kosar Doraghi talk contribs created page File:IMG 0788.jpeg
- 04:56, 7 February 2024 Kosar Doraghi talk contribs uploaded File:IMG 0788.jpeg
- 00:47, 7 February 2024 Edzelco talk contribs created page Lutetium (177Lu) vipivotide tetraxetan (Created page with "{{DrugProjectFormSinglePage |genericName=lutetium (177Lu) vipivotide tetraxetan |aOrAn=a |drugClass=radioligand therapeutic agent |indicationType=treatment |indication=adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor (AR) pathway inhibition and taxane-based chemotherapy |adverseReactions=fatigue, dry mout...")
- 00:44, 7 February 2024 Edzelco talk contribs created page File:Pluvicto label.png
- 00:44, 7 February 2024 Edzelco talk contribs uploaded File:Pluvicto label.png
- 00:44, 7 February 2024 Edzelco talk contribs created page File:Pluvicto structure.png
- 00:44, 7 February 2024 Edzelco talk contribs uploaded File:Pluvicto structure.png
- 22:17, 6 February 2024 Kosar Doraghi talk contribs created page File:IMG 0786.jpeg
- 22:17, 6 February 2024 Kosar Doraghi talk contribs uploaded File:IMG 0786.jpeg
- 22:07, 6 February 2024 Kosar Doraghi talk contribs created page File:IMG 0785.jpeg
- 22:07, 6 February 2024 Kosar Doraghi talk contribs uploaded File:IMG 0785.jpeg
- 22:05, 6 February 2024 Kosar Doraghi talk contribs created page File:IMG 0782.jpeg
- 22:05, 6 February 2024 Kosar Doraghi talk contribs uploaded File:IMG 0782.jpeg
- 21:45, 6 February 2024 Kosar Doraghi talk contribs created page File:IMG 0783.jpeg
- 21:45, 6 February 2024 Kosar Doraghi talk contribs uploaded File:IMG 0783.jpeg
- 21:44, 6 February 2024 Kosar Doraghi talk contribs created page File:IMG 0784.jpeg
- 21:44, 6 February 2024 Kosar Doraghi talk contribs uploaded File:IMG 0784.jpeg
- 21:18, 6 February 2024 Kosar Doraghi talk contribs created page Deucravacitinib (Created page with "{{DrugProjectFormSinglePage |authorTag=Kosar Doraghi, M.D.[mailto:k.doraghi@yahoo.com] |genericName=Deucravacitinib (SOTYKTU) |aOrAn=a |drugClass=tyrosine kinase 2 (TYK2) inhibitor |indicationType=treatment |indication=treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy |hasBlackBoxWarning=Yes |adverseReactions=hypersensitivity reaction, upper respiratory infections, blood creatine phosphokinase increased,...")
- 00:57, 6 February 2024 Edzelco talk contribs created page Nivolumab and relatlimab-rmbw (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} |genericName=nivolumab and relatlimab-rmbw |aOrAn=a |drugClass=combination of nivolumab, a programmed death receptor-1 (PD-1) blocking antibody, and relatlimab, a lymphocyte activation gene-3 (LAG-3) blocking antibody |indicationType=treatment |indication=adult and pediatric patients 12 years of age or older with unresectable or metastatic melanoma |adverseReactions=immune-mediated pneumonitis, im...")
- 00:56, 6 February 2024 Edzelco talk contribs created page File:Nivolumab and relatlimab-rmbw label.png
- 00:56, 6 February 2024 Edzelco talk contribs uploaded File:Nivolumab and relatlimab-rmbw label.png
- 00:22, 6 February 2024 Edzelco talk contribs created page File:Ganaloxone bottle carton.png
- 00:22, 6 February 2024 Edzelco talk contribs uploaded File:Ganaloxone bottle carton.png
- 00:22, 6 February 2024 Edzelco talk contribs created page File:Ganaloxone bottle suspension label 50mg.png
- 00:22, 6 February 2024 Edzelco talk contribs uploaded File:Ganaloxone bottle suspension label 50mg.png
- 00:21, 6 February 2024 Edzelco talk contribs created page File:Ganaloxone structure.png
- 00:21, 6 February 2024 Edzelco talk contribs uploaded File:Ganaloxone structure.png
- 06:00, 5 February 2024 Kosar Doraghi talk contribs created page File:IMG 0781.jpeg
- 06:00, 5 February 2024 Kosar Doraghi talk contribs uploaded File:IMG 0781.jpeg
- 05:49, 5 February 2024 Kosar Doraghi talk contribs created page RELYVRIO (Created page with "{{DrugProjectFormSinglePage |authorTag=Kosar Doraghi, M.D.[mailto:k.doraghi@yahoo.com] |genericName=sodium phenylbutyrate/taurursodiol |aOrAn=a |drugClass=drug that containing the active ingredients sodium phenylbutyrate and taurursodiol |indicationType=treatment |indication=amyotrophic lateral sclerosis (ALS) in adults. |hasBlackBoxWarning=Yes |adverseReactions=diarrhea, abdominal discomfort , nausea, and upper respiratory tract infection |blackBo...")